Advances in Therapy最新文献

{"title":"An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.","authors":"Jothydev Kesavadev, Anjana Basanth, Arun Shankar, Banshi Saboo, Anjana Ranjit Mohan, Shashank Joshi, Sujoy Ghosh, Gopika Krishnan, Krishnadev Jothydev, Asha Ashik","doi":"10.1007/s12325-025-03250-3","DOIUrl":"https://doi.org/10.1007/s12325-025-03250-3","url":null,"abstract":"<p><p>The management of diabetes has seen significant advancements with the introduction of various injectable therapies. Being a common chronic disorder, it is managed by doctors across all specialties worldwide. Despite the availability of new medications, healthcare professionals continue to face ambiguity due to differing terminologies and variations in regional practices. This review aims to elucidate the current therapeutic spectrum of injectable therapies in diabetes care, providing clarity on the types, mechanisms, and clinical implications of both insulin and non-insulin injections. An extensive review of existing literature was conducted, focusing on insulin injections (including short-acting, rapid-acting, ultra-rapid acting, intermediate-acting, long acting and ultra-long-acting types), non-insulin injections (such as glucagon-like peptide-1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] agonist, and amylin analogs) and co-formulations (long-acting insulin with GLP-1 or long-acting insulin with rapid acting insulin). We have included innovators and biosimilars in this review article for better understanding. Insulin therapies offer tailored glycemic control, while non-insulin injectables provide additional benefits in weight management and reduced hypoglycemia risk. This review serves as a comprehensive guide for healthcare providers worldwide to navigate the landscape of injectable treatment options in diabetes, with a focus on optimizing therapeutic outcomes through informed decision-making.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies.","authors":"Alessio Novella, Luciano Quaranta, Luca Pasina, Alessia A Galbussera, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Robert N Weinreb, Alessandro Nobili","doi":"10.1007/s12325-025-03247-y","DOIUrl":"https://doi.org/10.1007/s12325-025-03247-y","url":null,"abstract":"<p><strong>Introduction: </strong>The present study aimed to analyze drug utilization, adherence, and predictors of therapy changes and discontinuation among incident patients with glaucoma in the Lombardy Region of Italy.</p><p><strong>Methods: </strong>A cohort of 10,515 incident patients with glaucoma aged 50 years or older was identified from the Lombardy Region database. Patients were included if they received at least three consecutive prescriptions of antiglaucoma medications in 2010, with follow-up until December 31, 2018. Outcomes included drug utilization patterns, adherence (defined as covering ≥ 80% of follow-up days with medication), and predictors of therapy changes or discontinuation. Survival analysis and Cox regression models were used to assess time to therapy modification or discontinuation, adjusted for age, sex, chronic polypharmacy, and initial drug class.</p><p><strong>Results: </strong>The mean age of the cohort was 70.2 years, with 54.8% women. Beta-blocking agents (37.8%), timolol combinations (26.2%), and prostaglandin analogues (25.2%) were the most prescribed initial therapies. Only 41.0% of patients were adherent to therapy. Over the follow-up period, 73.4% of patients modified or discontinued their initial therapy, with a median time to the first change of 666 days. Older age (hazard ratio, HR = 1.16, 95% confidence interval, CI 1.09-1.25) and chronic polypharmacy (HR = 1.12, 95% CI 1.07-1.17) were significant predictors of therapy modification. Discontinuation occurred in 64.2% of patients, with a median time of 1156 days. Older age (HR = 1.25, 95% CI 1.16-1.34) and chronic polypharmacy (HR = 1.21, 95% CI 1.15-1.27) were also predictors of discontinuation. Prostaglandin analogues and beta-blocking agents were associated with lower risks of therapy modification and discontinuation compared to other drug classes.</p><p><strong>Conclusion: </strong>Older age and chronic polypharmacy were key predictors of therapy changes and discontinuation. Prostaglandin analogues and beta-blocker agents demonstrated greater therapy stability. These findings emphasize further need for targeted interventions to improve adherence and persistence, particularly among older patients and those with complex medication regimens.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Metabolic Improvements with Low-Dose Metformin Combined with Oral Contraceptives in Female Adolescents with PCOS: A Single-Center Retrospective Cohort Study.","authors":"Salvatore Giovanni Vitale, Stefano Di Michele, Alice Tassi, Claudia Succu, Stefano Angioni, Anna Maria Fulghesu","doi":"10.1007/s12325-025-03251-2","DOIUrl":"https://doi.org/10.1007/s12325-025-03251-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate metformin treatment's immediate and long-term efficacy in adolescent patients with polycystic ovary syndrome (PCOS) and hyperinsulinemia and the subsequent metabolic evolution post-treatment discontinuation.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study included 168 adolescent girls (12-17 years) diagnosed with PCOS between December 2018 and August 2024. All participants underwent an oral glucose tolerance test to evaluate insulin sensitivity and were stratified into two groups: patients with normal insulinemia (n = 21) and patients with hyperinsulinemia (n = 147). Patients with hyperinsulinemia were offered low-dose metformin (500 mg twice daily); 80 accepted and formed the treatment arm, while 53 declined and served as controls. Simultaneously, every subject received a continuous regimen of combined oral contraceptives (COCs) (30 µg ethinyl estradiol/3 mg drospirenone). Clinical, biochemical, and ultrasound assessments were conducted at baseline, at regular intervals during therapy, at the end of treatment, and at least 24 months after metformin discontinuation to evaluate immediate and long-term outcomes.</p><p><strong>Results: </strong>Metformin therapy yielded favorable body mass index, insulin sensitivity, and androgenic profile outcomes. Remarkably, these benefits persisted beyond the cessation of treatment. Metformin responders showed a ≥ 20% decrease in the insulin area under the curve values post-treatment. Our investigation revealed a substantial reduction in insulin resistance indices, evident both after therapy (p < 0.001) and during post-therapy follow-up (p = 0.001) compared to baseline values. Furthermore, patients showed improvements in clinical hyperandrogenism and reductions in ovarian volume.</p><p><strong>Conclusions: </strong>Our study highlights the effectiveness of low-dose metformin therapy in improving insulin resistance and metabolic parameters among adolescent patients with PCOS. Sustained benefits were observed even after treatment cessation. These findings underscore the potential for early intervention with metformin during adolescence to confer long-lasting advantages in managing metabolic abnormalities associated with PCOS.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.","authors":"Dimitrios Pantazopoulos, Evanthia Gouveri, Massimo Papi, Dimitrios Papazoglou, Nikolaos Papanas","doi":"10.1007/s12325-025-03257-w","DOIUrl":"https://doi.org/10.1007/s12325-025-03257-w","url":null,"abstract":"<p><p>Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is) are well-established agents for type 2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits in psoriasis, while DPP-4is may reduce the risk of melanoma. Moreover, both of these agents may play a pivotal role in improving wound healing. However, untoward effects, such as bullous pemphigoid, highlight the need for patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Safety and Effectiveness of Vosoritide in Achondroplasia: Results from a Single Center in Portugal.","authors":"Inês B Rua, Isabel Silva, Christoph Beger, Cristina Gomes, Maria J Pais, Alice Mirante, Sérgio B Sousa","doi":"10.1007/s12325-025-03223-6","DOIUrl":"https://doi.org/10.1007/s12325-025-03223-6","url":null,"abstract":"<p><strong>Introduction: </strong>Achondroplasia, the most common skeletal dysplasia, is caused by autosomal dominant gain-of-function pathogenic variants in the fibroblast growth factor receptor 3 (FGFR3) gene. Vosoritide, a C-type natriuretic peptide analog, is a first-in-class targeted treatment for achondroplasia that counteracts overactive FGFR3 signaling to stimulate endochondral bone growth. This retrospective cohort study evaluated growth, safety, and treatment compliance in children with achondroplasia receiving vosoritide under an early access program in Portugal.</p><p><strong>Methods: </strong>Twenty-seven children aged 2-14 years with a genetically confirmed diagnosis of achondroplasia were treated with vosoritide at a single Portuguese center for at least 6 months between January 2022 and June 2024. The analysis included children with severe achondroplasia-associated complications. Anthropometric measurements collected to characterize the effect of vosoritide on growth included height standard deviation score (SDS) and annualized growth velocity (AGV). Student's t test was used for statistical comparisons. Safety and tolerability endpoints included adverse drug reactions and treatment adherence.</p><p><strong>Results: </strong>In total, 15 children completed at least 24 months of treatment. After 24 months of treatment, mean variation in height SDS increased from baseline by + 0.95 SD (P ≤ 0.0001), referenced to an untreated achondroplasia-specific population, and + 0.56 SD (P ≤ 0.0001) relative to children of average stature. Additionally, mean AGV from baseline was 5.87 cm/year (95% confidence interval 5.14-6.60), resulting in a significant increase of + 1.62 cm/year (P ≤ 0.0001). Injection site reactions were the most common adverse drug reaction observed (n = 14); no serious adverse drug reactions were reported. There were no discontinuations due to adverse drug reactions.</p><p><strong>Conclusion: </strong>Vosoritide showed long-term effectiveness in a real-world Portuguese population of patients with achondroplasia. Vosoritide was also well tolerated, and patients showed good adherence to treatment. These findings were consistent with the outcomes of clinical trials and existing real-world experience.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder.","authors":"Andrew J Cutler, Hemangi R Panchmatia, Alejandro G Hughes, Noah S Webb, Michael J Doane, Rakesh Jain","doi":"10.1007/s12325-025-03211-w","DOIUrl":"https://doi.org/10.1007/s12325-025-03211-w","url":null,"abstract":"<p><strong>Introduction: </strong>A combination of olanzapine and samidorphan (OLZ/SAM), approved by the US Food and Drug Administration (2021) for the treatment of adults with schizophrenia (SZ) or bipolar I disorder (BD-I), mitigates weight gain associated with olanzapine treatment. This study examined changes in healthcare resource utilization (HCRU) among patients with SZ or BD-I after initiating OLZ/SAM.</p><p><strong>Methods: </strong>This retrospective analysis utilized USA-based administrative claims data from April 19, 2021 to December 31, 2022. Adults aged ≥ 18 years with SZ or BD-I who had continuous enrollment ≥ 6 months before (baseline) and after (follow-up) OLZ/SAM initiation (index) were eligible. HCRU comparisons included inpatient admissions, average number of inpatient days, emergency department (ED) visits, and outpatient visits between 6-month baseline and follow-up periods.</p><p><strong>Results: </strong>In total, 1546 patients initiated OLZ/SAM (SZ: n = 855, mean age 39.4 years, 52.6% male; BD-I: n = 691, 38.4 years, 31.0% male). Overall, 446 (52.2%) patients with SZ and 302 (43.7%) patients with BD-I remained on OLZ/SAM during the full 6-month follow-up (median days persistent 182 and 106, respectively). In the SZ and BD-I cohorts, proportions of patients with all-cause and mental health (MH)-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all-cause: all P ≤ 0.026; MH-related: all P < 0.001). Findings were similar for disease-specific outcomes with the exception that reductions in BD-I-related ED visits were not significant. Average number of inpatient days decreased after OLZ/SAM initiation in both cohorts; in patients with BD-I, those reductions were statistically significant (all P ≤ 0.022). The proportions of patients with outpatient visits were similar between baseline and follow-up for both cohorts.</p><p><strong>Conclusions: </strong>Results from this first real-world study assessing HCRU after OLZ/SAM initiation suggest that OLZ/SAM results in reductions in burden for patients, providers, and the healthcare system, as evidenced by reductions in acute all-cause, MH-related, and disease-specific HCRU among SZ and BD-I cohorts.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.","authors":"Jonathan Douxfils, Emma Boretti, Charlotte Beaudart, Jean-Michel Dogné","doi":"10.1007/s12325-025-03242-3","DOIUrl":"https://doi.org/10.1007/s12325-025-03242-3","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review.","authors":"Dimitrios Pantazopoulos, Stella Papachristou, Evanthia Gouveri, Massimo Papi, Dimitrios Papazoglou, Nikolaos Papanas","doi":"10.1007/s12325-025-03256-x","DOIUrl":"https://doi.org/10.1007/s12325-025-03256-x","url":null,"abstract":"<p><p>Metformin, a well-established, first-line therapy for type 2 diabetes mellitus, is still gaining interest for its potential applications beyond glycaemic control. In addition to its insulin-sensitising effects, metformin exhibits anti-inflammatory, antioxidant, anti-proliferative, and immunomodulatory properties, rendering it a promising candidate for various dermatological conditions. Emerging evidence suggests that metformin may play a beneficial role in inflammatory skin diseases, such as acne, hidradenitis suppurativa, acanthosis nigricans, rosacea and psoriasis. Furthermore, recent studies highlight its potential in promoting wound healing and modulating skin ageing. This narrative review summarises current knowledge of the mechanisms of action of metformin in dermatology and explores its potential as a novel therapeutic approach for skin disorders.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.","authors":"Xuewen Song, Feng Xue, Lingling Chen, Donghui Yuan, Yifan Yang, Huiyuan Li, Lei Zhang, Shawn X Sun, Jia Zhong, Eric Wu, Renchi Yang","doi":"10.1007/s12325-025-03151-5","DOIUrl":"https://doi.org/10.1007/s12325-025-03151-5","url":null,"abstract":"<p><strong>Introduction: </strong>Despite concerted efforts of healthcare agencies, haemophilia treatment coverage remains inadequate in China. This real-world study was conducted to understand patient characteristics, clinical and economic burden, and treatment patterns amongst patients with haemophilia A in China with the aim of improving patient outcomes and quality of life.</p><p><strong>Methods: </strong>Two data sources, namely the National Haemophilia Registry and Institute of Haematology and Blood Diseases Hospital, were used to analyse the disease burden, treatment patterns and economic burden of haemophilia A in China. The economic burden was assessed from 2017 to 2019.</p><p><strong>Results: </strong>Overall, 3164 male patients with haemophilia A (mean age 21.5 years) were analysed. Almost half (48.3%) of the patients were children or adolescents; amongst them, 13.5% were enrolled from Guangdong and 10.7% from Hebei. Furthermore, 58.9% of the patients had severe haemophilia A. The most common sites for the first bleeding and bleeding during disease course were skin/mucous membrane (40.0%) and joints (77.9%), respectively. Plasma-derived factor VIII constituted the most frequently used therapy (45.8% of patients) and only 30.1% of patients used a prophylactic treatment. The hospitalisation rate increased from 8% in 2017 to 21% in 2019, whereas 63% to 75% of patients had outpatient visits during each year. The total annual cost of treating haemophilia (hospitalisation plus outpatient) including the cost of FVIII replacement per patient was 57,439.4 CNY.</p><p><strong>Conclusion: </strong>Suboptimal disease management and low utilisation of prophylaxis are the main challenges for patients with haemophilia A in China. Therefore, continued efforts to improve disease awareness and treatment accessibility are required.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.","authors":"Risa Kagan, Antonio Cano, Rossella E Nappi, Marci L English, Shayna Mancuso, Xi Wu, Faith D Ottery","doi":"10.1007/s12325-025-03243-2","DOIUrl":"https://doi.org/10.1007/s12325-025-03243-2","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}